

# MEDICINES RECALL

## CLASS 2 MEDICINES RECALL, EL(26)A/01

**Action within 48 hours**

Issued 20 January 2026

Distribute to Pharmacy/Wholesaler Level

### MARKETING AUTHORISATION HOLDER (MAH)

Mercury Pharmaceuticals Ltd

### MEDICINE DETAILS

**Paliperidone Mercury Pharma 50 mg prolonged-release suspension for injection in pre-filled syringe**

PLGB 12762/0671

Active Ingredient: paliperidone palmitate

SNOMED code: 41440511000001105

GTIN: 05021691003700

### AFFECTED LOT BATCH NUMBERS

Batch No.	Expiry Date	Pack Size	First Distributed
4400353	30/06/2026	1s	19/03/2024
4301747	30/09/2026	1s	18/12/2023
4400797	30/09/2026	1s	24/07/2024
4401269	30/09/2026	1s	04/02/2025
4401271	30/09/2026	1s	13/02/2025

## MEDICINE DETAILS

### Paliperidone Mercury Pharma 75 mg prolonged-release suspension for injection in pre-filled syringe

PLGB 12762/0672

Active Ingredient: paliperidone palmitate

SNOMED code: 41440711000001100

GTIN: 05021691003717

## AFFECTED LOT BATCH NUMBERS

Batch No.	Expiry Date	Pack Size	First Distributed
4301534	30/06/2026	1s	01/11/2023
4301945	30/06/2026	1s	26/01/2024
4301883	30/09/2026	1s	11/01/2024
4400979	30/09/2026	1s	05/12/2024
4400711	31/10/2026	1s	24/07/2024
4401437	30/06/2027	1s	27/02/2025
4500150R	31/12/2027	1s	14/07/2025
4500154R	31/12/2027	1s	24/07/2025
4500171R	31/12/2027	1s	01/08/2025
4500176	31/01/2028	1s	Quarantined at wholesaler
4500443R	31/03/2028	1s	11/09/2025
4501272	31/08/2028	1s	Quarantined at wholesaler

## MEDICINE DETAILS

**Paliperidone Mercury Pharma 100 mg prolonged-release suspension for injection in pre-filled syringe**

PLGB 12762/0673

Active Ingredient: paliperidone palmitate

SNOMED code: 41440911000001103

GTIN: 05021691003724

## AFFECTED LOT BATCH NUMBERS

Batch No.	Expiry Date	Pack Size	First Distributed
4301518	30/06/2026	1s	08/11/2023
4301550	30/06/2026	1s	08/12/2023
4301970	30/06/2026	1s	25/01/2024
4400390	30/06/2026	1s	21/03/2024
4400737	30/06/2026	1s	24/07/2024
4401361	30/06/2027	1s	06/12/2024
4500100	31/12/2027	1s	29/04/2025
4500280	31/01/2028	1s	26/06/2025
4500675	31/05/2028	1s	28/07/2025
4500750	31/05/2028	1s	20/08/2025
4500825	31/05/2028	1s	28/10/2025
4500894	31/05/2028	1s	Quarantined at wholesaler
4501516	30/09/2028	1s	Quarantined at wholesaler

## MEDICINE DETAILS

### Paliperidone Mercury Pharma 150 mg prolonged-release suspension for injection in pre-filled syringe

PLGB 12762/0674

Active Ingredient: paliperidone palmitate

SNOMED code: 41441111000001107

GTIN: 05021691003731

## AFFECTED LOT BATCH NUMBERS

Batch No.	Expiry Date	Pack Size	First Distributed
4301538	30/06/2026	1s	26/10/2023
4301930	30/06/2026	1s	26/01/2024
4301817	30/09/2026	1s	01/12/2023
4401337	30/09/2026	1s	05/12/2024
4401338	30/09/2026	1s	09/12/2024
4401277	30/09/2026	1s	04/02/2025
4400150	31/10/2026	1s	11/04/2024
4400169	31/12/2026	1s	04/06/2024
4500200	31/01/2028	1s	23/05/2025
4500197R	31/01/2028	1s	13/08/2025
4500596	30/04/2028	1s	15/07/2025
4500689	30/04/2028	1s	05/08/2025
4500709R	31/05/2028	1s	30/10/2025
4501340	31/07/2028	1s	06/11/2025
4501371	31/08/2028	1s	09/12/2025

### Background

Mercury Pharmaceuticals Ltd is recalling remaining stock of paliperidone pre-filled syringes as a precautionary measure due to Good Manufacturing Practice (GMP) deficiencies cited during a recent inspection at the finished product manufacturing site. Mercury Pharmaceuticals Ltd has confirmed that due to the ongoing remedial actions at the finished product manufacturing site, there may be delays in the manufacture of future batches.

#### Advice for Healthcare Professionals:

Stop supplying the above batches immediately. Quarantine all stock and return it to your supplier using your supplier's approved process.

Where appropriate, healthcare professionals involved in dispensing practices (pharmacy teams, homecare teams etc), should contact patients to advise them to contact their prescriber for a review to ensure that an alternative product is available, without delaying their treatment.

Where Paliperidone Mercury Pharma prolonged-release injections are unavailable, clinicians should ensure continuity of treatment and consider appropriate alternative licensed treatment options. These may include an alternative paliperidone palmitate product, another long-acting injectable antipsychotic, or, where clinically appropriate, an oral antipsychotic (including oral paliperidone or risperidone), in line with local formularies, NICE guidance, and individual patient needs. For some patients, oral treatment may be considered as a temporary bridging option until long-acting injectable therapy can be resumed. Switching between treatments should be planned to avoid missed doses and minimise the risk of relapse, with appropriate clinical monitoring for efficacy and tolerability, particularly during the initial period following a change in treatment.

No specific safety concerns have been identified with the affected batches, and a review of the company safety database has not identified any increase in adverse events associated with this issue.

#### Advice for Healthcare Professionals to Provide to Patients:

This recall is precautionary and relates to manufacturing standards rather than a confirmed problem with the medicine itself.

Patients are advised to contact their prescriber as soon as possible to arrange treatment without interruption. Patients should continue to take the medication until they have arranged alternative treatment.

Mercury Pharmaceuticals Ltd has not identified any adverse events related to this issue. A review of the company's safety data has not identified any safety concerns associated with the affected batches. Patients who have already received injections from the affected batches do not

require any additional monitoring beyond routine clinical care unless they have concerns or experience new symptoms.

Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the [MHRA Yellow Card scheme](#).

### **Additional information:**

The final date for recalled stock to be received for credit is **06 March 2026**. For stock enquiries please contact Advanz Pharma Customer Care Services on +44 (0) 208 588 9441 or email [customercare@advanzpharma.com](mailto:customercare@advanzpharma.com)

For medical information enquiries please contact Advanz Pharma Medical Information on +44 (0) 208 588 9131 or email [medicalinformation@advanzpharma.com](mailto:medicalinformation@advanzpharma.com)

Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

**Yours faithfully**

**Defective Medicines Report Centre**

**10 South Colonnade**

**Canary Wharf**

**London E14 4PU**

**Telephone +44 (0)20 3080 6574**

**[DMRC@MHRA.gov.uk](mailto:DMRC@MHRA.gov.uk)**